Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2026-01-02 @ 3:06 AM
Study NCT ID:
NCT05934292
Status:
COMPLETED
Last Update Posted:
2025-02-17
First Post:
2023-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-01-19
Completion Date Type:
ACTUAL
First Submit Date:
2023-06-05
First Submit QC Date:
None
Study First Post Date:
2023-07-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-12-12
Results First Submit QC Date:
None
Results First Post Date:
2025-02-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-12
Last Update Post Date:
2025-02-17
Last Update Post Date Type:
ACTUAL